Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme.
International journal of psychiatry in clinical practice November 2022 Ludovic Samalin, Maud Rothärmel, Lila Mekaoui et al.
To present the first real-world data of patients with treatment-resistant depression (TRD) treated with esketamine through a French cohort Temporary Authorisation for Use (ATUc) programme. In 2019, the French Health Authorities exceptionally granted the first ATUc in psychiatry for TRD patients. Clinical characteristics, safety and efficacy data were reported by physicians. The ATUc ended ∼6...